These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

823 related items for PubMed ID: 16145413

  • 1. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT, Rademaker A, Lloyd GL, Gann P.
    J Urol; 2005 Oct; 174(4 Pt 1):1327-433. PubMed ID: 16145413
    [Abstract] [Full Text] [Related]

  • 2. [The autonomic nervous system function in benign prostatic hyperplasia].
    Thor PJ, Mazur M, Furgała A, Worek M.
    Folia Med Cracov; 2006 Oct; 47(1-4):79-86. PubMed ID: 18038615
    [Abstract] [Full Text] [Related]

  • 3. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
    Antunes AA, Srougi M, Dall'oglio MF, Vicentini F, Paranhos M, Freire GC.
    J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
    [Abstract] [Full Text] [Related]

  • 4. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E, Bientinesi R, Marangi F, Totaro A, D'Addessi A, Racioppi M, Pinto F, Vittori M, Bassi P.
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L, LVHJ study team.
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [Abstract] [Full Text] [Related]

  • 6. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.
    Corica FA, Jacobsen SJ, King BF, Bostwick DG, Jacobson DJ, Girman CJ, Lieber MM.
    J Urol; 1999 Mar; 161(3):831-4. PubMed ID: 10022695
    [Abstract] [Full Text] [Related]

  • 7. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L.
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [Abstract] [Full Text] [Related]

  • 8. Data from frequency-volume charts versus symptom scores and quality of life score in men with lower urinary tract symptoms due to benign prostatic hyperplasia.
    van Venrooij GE, Eckhardt MD, Gisolf KW, Boon TA.
    Eur Urol; 2001 Jan; 39(1):42-7. PubMed ID: 11173938
    [Abstract] [Full Text] [Related]

  • 9. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC, Rosenberg M, Kissel J, Wong DG.
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [Abstract] [Full Text] [Related]

  • 10. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.
    Lee JH, Kim Y, Park YW, Lee DG.
    J Sex Med; 2014 May; 11(5):1309-15. PubMed ID: 24612680
    [Abstract] [Full Text] [Related]

  • 11. Comprehensive patient evaluation for benign prostatic hyperplasia.
    Jepsen JV, Bruskewitz RC.
    Urology; 1998 Apr; 51(4A Suppl):13-8. PubMed ID: 9586591
    [Abstract] [Full Text] [Related]

  • 12. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K.
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [Abstract] [Full Text] [Related]

  • 13. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
    Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DE, Padley RJ.
    Urology; 1996 Feb; 47(2):159-68. PubMed ID: 8607227
    [Abstract] [Full Text] [Related]

  • 14. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK.
    Trueman P, Hood SC, Nayak US, Mrazek MF.
    BJU Int; 1999 Mar; 83(4):410-5. PubMed ID: 10210562
    [Abstract] [Full Text] [Related]

  • 15. Symptoms, prostate volume, and urodynamic findings in elderly male volunteers without and with LUTS and in patients with LUTS suggestive of benign prostatic hyperplasia.
    Eckhardt MD, van Venrooij GE, Boon TA.
    Urology; 2001 Dec; 58(6):966-71. PubMed ID: 11744470
    [Abstract] [Full Text] [Related]

  • 16. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S.
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.